by Klaira Lerma, Paul D Blumenthal
BMJ Sexual & Reproductive Health 07 March 2023. doi: 10.1136/bmjsrh-2022-201775 (Not open access)
Abstract
Objective: To assess interest in clinician-administered advance provision of abortion pills among potential users in the USA.
Methods: Using social media advertisements, we recruited people living in the USA who were aged 18–45 years and assigned female at birth, who were not pregnant or planning pregnancy, for an online survey on reproductive health experiences and attitudes. We explored interest in advance provision of abortion pills, participant characteristics, including demographics and pregnancy history, contraceptive use, abortion knowledge and comfort, and healthcare system distrust. We used descriptive statistics to assess interest in advance provision, and ordinal regression modelling to evaluate differences in interest controlling for age, pregnancy history, contraceptive use, familiarity and comfort with medication abortion, and healthcare system distrust, reporting adjusted odds ratios (aORs) and 95% confidence intervals (95% CIs).
Results: From January-February 2022, we recruited 634 diverse respondents from 48 states, among whom 65% were interested, 12% neutral, and 23% disinterested in advance provision. There were no differences among interest groups by US region, race/ethnicity, or income. In the model, variables associated with interest included being aged 18–24 years versus 35–45 years, using a tier 1 (permanent or long-acting reversible) or tier 2 (short-acting hormonal) contraceptive method versus no contraception, being familiar or comfortable with the medication abortion process, and having high healthcare system distrust versus low distrust.
Conclusion: As abortion access becomes more constrained, strategies are needed to ensure timely access. Advance provision is of interest to the majority of those surveyed and warrants further policy and logistical exploration.
VISUAL: https://twitter.com/Plancpills/status/1433201849214148611